This course was last updated on
April 19, 2017
CME credit has expired.


The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review answers to some of the most important questions posed by your oncology and urology colleagues from a series of live Tumor Boards.

Check your own knowledge with 5 short assessment questions.

Discover the top questions oncologists and urologists have about castration-resistant prostate cancer.

Probe the details of a related patient case.

Content Areas

  • Androgen deprivation resistance
  • Prechemotherapy vs postchemotherapy
  • Sequencing therapy
  • Shared decision making

Target Audience

This activity was developed for hospital-based oncologists and urologists, community cancer center oncologists, oncology fellows and other health care professionals involved in the management of patients with castration-resistant prostate cancer (CRPC).

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.


Oliver Sartor, MD
Oliver Sartor, MD
Medical Director
Tulane Cancer Center
New Orleans, Louisiana
Charles Ryan, MD
Charles Ryan, MD
Professor of Clinical Medicine and Urology
Clinical Program Leader for Genitourinary Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Evan Ya-Wen Yu, MD
Evan Ya-Wen Yu, MD
Associate Professor, Department of Medical Oncology
University of Washington School of Medicine
Associate Member, Fred Hutchinson Cancer Research Center
Seattle, Washington
Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
Course Opens: April 19, 2017
Course Expires: April 18, 2018
Target Audience: Oncologists
Other Health Care Providers